The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with metronidazole for patients 18 years and older who have limited or no alternative options for the ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI ...

Emblaveo was developed in partnership with Pfizer ... antibiotic’s commercialization in the rest of the world. — The FDA sent Harmony Biosciences a refuse to file letter for pitolistant ...

The healthcare sector, too, has seen advances with AbbVie's EMBLAVEO™ gaining FDA approval for a combination antibiotic, and the European Medicines Agency recommending its arthritis treatment ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options. The CDC on Thursday published its famed ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including the formation of ALS United, global sleep study results from IKEA and FDA approval of EMBLAVEO™.

This collaborative approach, alongside the FDA approval of innovative products like EMBLAVEO, has reinforced investor confidence. Despite facing challenges such as fluctuating profit margins and ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with ...

The healthcare sector, too, has seen advances with AbbVie's EMBLAVEO™ gaining FDA approval for a combination antibiotic, and the European Medicines Agency recommending its arthritis treatment, RINVOQ® ...